95 related articles for article (PubMed ID: 15849866)
21. Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat.
Tayarani-Binazir KA; Jackson MJ; Strang I; Jairaj M; Rose S; Jenner P
Behav Pharmacol; 2012 Apr; 23(2):126-33. PubMed ID: 22236652
[TBL] [Abstract][Full Text] [Related]
22. [The morphochemical characteristics of the brain in Wistar rats that differ by open-field motor activity].
Gershteĭn LM; Kamysheva AS; Chebotareva TL; Sergutina AV; Orlova EI
Zh Vyssh Nerv Deiat Im I P Pavlova; 1991; 41(2):300-5. PubMed ID: 1651620
[TBL] [Abstract][Full Text] [Related]
23. Modification of inherent and drug-induced dopaminergic activity after exposure to benzo(alpha)pyrene.
Konstandi M; Harkitis P; Thermos K; Ogren SO; Johnson EO; Tzimas P; Marselos M
Neurotoxicology; 2007 Jul; 28(4):860-7. PubMed ID: 17570529
[TBL] [Abstract][Full Text] [Related]
24. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
Johansson PA; Andersson M; Andersson KE; Cenci MA
Neurobiol Dis; 2001 Apr; 8(2):220-39. PubMed ID: 11300719
[TBL] [Abstract][Full Text] [Related]
25. Altered behavioural and neurochemical profile of L-DOPA following deuterium substitutions in the molecule.
Malmlöf T; Svensson TH; Schilström B
Exp Neurol; 2008 Aug; 212(2):538-42. PubMed ID: 18561915
[TBL] [Abstract][Full Text] [Related]
26. Intranasally applied L-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions.
Chao OY; Mattern C; Silva AM; Wessler J; Ruocco LA; Nikolaus S; Huston JP; Pum ME
Brain Res Bull; 2012 Feb; 87(2-3):340-5. PubMed ID: 22108632
[TBL] [Abstract][Full Text] [Related]
27. L-DOPA attenuates hyperactivity of Roborovskii hamsters.
Kabuki Y; Shigemi K; Hamasu K; Furuse M
Behav Pharmacol; 2009 May; 20(3):260-4. PubMed ID: 19404194
[TBL] [Abstract][Full Text] [Related]
28. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
[TBL] [Abstract][Full Text] [Related]
29. L-dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats.
Kääriäinen TM; García-Horsman JA; Piltonen M; Männistö PT
Neuroreport; 2009 Feb; 20(3):313-8. PubMed ID: 19188858
[TBL] [Abstract][Full Text] [Related]
30. Iron deficiency alters dopamine uptake and response to L-DOPA injection in Sprague-Dawley rats.
Bianco LE; Wiesinger J; Earley CJ; Jones BC; Beard JL
J Neurochem; 2008 Jul; 106(1):205-15. PubMed ID: 18363828
[TBL] [Abstract][Full Text] [Related]
31. [Cytochemical manifestations of short- and long-term activation of the dopaminergic system of the rat brain].
Gershteĭn LM; Chebotareva TL; Sergutina AV
Biull Eksp Biol Med; 1991 Jul; 112(7):41-2. PubMed ID: 1793849
[TBL] [Abstract][Full Text] [Related]
32. [Effect of L-DOPA on brain serotonin metabolism related to tryptophan concentrations in plasma and brain of rats].
Kohno Y
Nihon Yakurigaku Zasshi; 1981 Mar; 77(3):281-93. PubMed ID: 6188670
[TBL] [Abstract][Full Text] [Related]
33. Chronic salsolinol administration prevents the behavioral and neurochemical effects of L-DOPA in rats.
Wąsik A; Romańska I; Michaluk J; Antkiewicz-Michaluk L
Neurotox Res; 2015 May; 27(4):399-410. PubMed ID: 25711629
[TBL] [Abstract][Full Text] [Related]
34. Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
Marin C; Bonastre M; Mengod G; Cortés R; Giralt A; Obeso JA; Schapira AH
Neurobiol Dis; 2014 Apr; 64():36-47. PubMed ID: 24370700
[TBL] [Abstract][Full Text] [Related]
35. Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment.
Joyce JN; Der TC; Renish L; Osredkar T; Hagner D; Reploge M; Sakakibara S; Ueda S
Exp Neurol; 2004 May; 187(1):178-89. PubMed ID: 15081599
[TBL] [Abstract][Full Text] [Related]
36. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
[TBL] [Abstract][Full Text] [Related]
37. Dual effects of L-DOPA on nigral dopaminergic neurons.
Guatteo E; Yee A; McKearney J; Cucchiaroni ML; Armogida M; Berretta N; Mercuri NB; Lipski J
Exp Neurol; 2013 Sep; 247():582-94. PubMed ID: 23481547
[TBL] [Abstract][Full Text] [Related]
38. L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase.
Shimamura M; Shimizu M; Yagami T; Funabashi T; Kimura F; Kuroiwa Y; Misu Y; Goshima Y
Neuropharmacology; 2006 Jun; 50(8):909-16. PubMed ID: 16504219
[TBL] [Abstract][Full Text] [Related]
39. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y
Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306
[TBL] [Abstract][Full Text] [Related]
40. PDE10A mutation in two sisters with a hyperkinetic movement disorder - Response to levodopa.
Knopp C; Häusler M; Müller B; Damen R; Stoppe A; Mull M; Elbracht M; Kurth I; Begemann M
Parkinsonism Relat Disord; 2019 Jun; 63():240-242. PubMed ID: 30777652
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
